Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

NANot yet recruitingINTERVENTIONAL

Enrollment

225

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

AML, AdultMinimal Residual Disease

Interventions

DIAGNOSTIC_TEST

MRD assessment

Bone marrow withdrawal for MRD quantification

All Listed Sponsors

lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER

NCT06090786 - Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | Biotech Hunter | Biotech Hunter